Prosecution Insights
Prosecution Insights
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKHART, MICHAEL D | 1 | 62.2% | +11.5% |
| LYLE, SOPHIA YUAN | 1 | 57.7% | +59.0% |
| STEIN, LEAH ELIZABETH | 1 | 100.0% | +0.0% |
| BUNKER, AMY M | 1 | 29.1% | +45.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18271364 | Interleukin-37, Chimeric Antigen Receptors, Nucleic Acids, and Vectors Encoding the Same and Uses in Cancer Therapies | STEIN, LEAH ELIZABETH | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18273973 | Methods, Devices and Systems for Generating a Chemical Gradient | LYLE, SOPHIA YUAN | 1d overdue |
| 17919481 | Immune Cell Redirecting Compositions and Therapeutic Uses Thereof | BUNKER, AMY M | 30d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18273973 | Methods, Devices and Systems for Generating a Chemical Gradient | LYLE, SOPHIA YUAN | 1d overdue |
| 17919481 | Immune Cell Redirecting Compositions and Therapeutic Uses Thereof | BUNKER, AMY M | 30d |
| 18654622 | GENETICALLY ENGINEERED DRUG RESISTANT T CELLS AND METHODS OF USING THE SAME | BURKHART, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1796 | 1 |
| 1641 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18654622 | GENETICALLY ENGINEERED DRUG RESISTANT T CELLS AND METHODS OF USING THE SAME | BURKHART, MICHAEL D | — | §103§112DP | Non-Final OA | — | Pending | May 03, 2024 |
| 18273973 | Methods, Devices and Systems for Generating a Chemical Gradient | LYLE, SOPHIA YUAN | 1796 | §102§103§112 | Non-Final OA | 1d overdue | Pending | Jul 24, 2023 |
| 18271364 | Interleukin-37, Chimeric Antigen Receptors, Nucleic Acids, and Vectors Encoding the Same and Uses in Cancer Therapies | STEIN, LEAH ELIZABETH | 1641 | §103§112DP | Final Rejection | — | Pending | Jul 07, 2023 |
| 17919481 | Immune Cell Redirecting Compositions and Therapeutic Uses Thereof | BUNKER, AMY M | 1684 | §103 | Final Rejection | 30d | Pending | Oct 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial